Boston Business JournalCambridge startup Jounce to get $225m in Celgene dealThe Boston GlobeJounce Therapeutics Inc., a three-year-old Cambridge startup, has struck a collaboration deal with an upfront payment of $225 million to jointly develop cancer drugs with Celgene Corp. The agreement, potentially worth as much as $2.3 billion, will help ...Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development PactTheStreet.comCelgene (CELG), Jounce Therapeutics Enter Immuno-oncology Development CollaborationStreetInsider.comCambridge's Jounce announces hefty $2.5B deal with Celgene for cancer drugsBoston Business Journal (blog)MarketWatch -Financial Timesall 10 news articles »